Long acting GLP-1 receptor agonist (injectable)
Ecnoglutide 0.4 mg injection once weekly
ECNO_SC_0p4MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.22 (-1.95 to -0.38) | 0.51 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.03 (-6.44 to 2.58) | 0.66 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.41 (0.01 to 17.45) | 0.64 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.42 (0.01 to 18.22) | 0.71 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.20 (0.17 to 8.74) | 0.67 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.34 (0.12 to 42.51) | 0.51 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.93 (0.87 to 24.12) | 0.21 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.89 (0.12 to 5.65) | 0.65 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.84 (0.05 to 13.49) | 0.47 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.64 (0.01 to 44.54) | 0.58 |